ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,585
0,00%
Bitcoin
60 901,57
0,18%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Nektar Therapeutics (NKTR)

  7. Nektar Therapeutics (NKTR) Actualités

NKTR

Nektar Therapeutics (NKTR)

Nektar Therapeutics
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NKTR
DateHeureSourceTitreSymboleSociété
09/05/202422h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
09/05/202422h15PR Newswire (US)Nektar Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:NKTRNektar Therapeutics
03/05/202400h00PR Newswire (US)Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
22/03/202419h00PR Newswire (US)Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceNASDAQ:NKTRNektar Therapeutics
05/03/202423h11Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NKTRNektar Therapeutics
05/03/202415h00PR Newswire (US)Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia AreataNASDAQ:NKTRNektar Therapeutics
04/03/202422h15PR Newswire (US)Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial ResultsNASDAQ:NKTRNektar Therapeutics
04/03/202414h30PR Newswire (US)Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGXNASDAQ:NKTRNektar Therapeutics
28/02/202400h00PR Newswire (US)Nektar Management to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:NKTRNektar Therapeutics
27/02/202400h00PR Newswire (US)Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
23/02/202402h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
20/02/202421h55Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
14/02/202423h03Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NKTRNektar Therapeutics
04/01/202400h00PR Newswire (US)Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CANASDAQ:NKTRNektar Therapeutics
12/12/202300h00PR Newswire (US)Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:NKTRNektar Therapeutics
07/11/202322h15PR Newswire (US)Nektar Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:NKTRNektar Therapeutics
31/10/202323h00PR Newswire (US)Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
13/10/202314h30PR Newswire (US)Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV CongressNASDAQ:NKTRNektar Therapeutics
02/10/202315h00PR Newswire (US)Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell TherapyNASDAQ:NKTRNektar Therapeutics
27/09/202315h00PR Newswire (US)Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung CancerNASDAQ:NKTRNektar Therapeutics
13/09/202315h00PR Newswire (US)Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic DermatitisNASDAQ:NKTRNektar Therapeutics
07/09/202300h00PR Newswire (US)Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13thNASDAQ:NKTRNektar Therapeutics
17/08/202322h30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NKTRNektar Therapeutics
12/08/202303h31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NKTRNektar Therapeutics
08/08/202322h15PR Newswire (US)Nektar Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:NKTRNektar Therapeutics
07/08/202312h30PR Newswire (US)Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & CompanyNASDAQ:NKTRNektar Therapeutics
02/08/202300h00PR Newswire (US)Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
23/06/202312h02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NKTRNektar Therapeutics
16/06/202300h27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NKTRNektar Therapeutics
14/06/202323h16Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:NKTRNektar Therapeutics
 Showing the most relevant articles for your search:NASDAQ:NKTR

Dernières Valeurs Consultées

EU
LR
Legrand
EU
RNO
Renault
NYSE
NKE
Nike
NYSE
MCD
McDonalds
USI
USTECH100
US Tech 100
EU
AI
Air Liquide
NASDAQ
NVDA
NVIDIA
EU
EN
Bouygues
EU
HO
Thales
EU
BEL20
Bel 20
EU
AF
Air FranceKLM
EU
BNP
BNP Paribas
EU
GLE
Societe Generale
NYSE
JPM
JP Morgan Chase
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés